<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03387761</url>
  </required_header>
  <id_info>
    <org_study_id>N17NAB</org_study_id>
    <secondary_id>CA209-9Y4</secondary_id>
    <nct_id>NCT03387761</nct_id>
  </id_info>
  <brief_title>Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy</brief_title>
  <acronym>NABUCCO</acronym>
  <official_title>Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In cohort 1 of this study, we used an attenuated schedule of neoadjuvant ipilimumab and&#xD;
      nivolumab. This cohort has now fully enrolled, and all eligible patients had resection of the&#xD;
      bladder &lt;12 weeks from 1st cycle (23/24, 96%). In the current multicenter extension (cohort&#xD;
      2), n=30 patients will be randomized between two neoadjuvant treatment schemes, both based&#xD;
      upon an attenuated schedule of neoadjuvant ipilimumab and nivolumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open-label phase Ib trial to evaluate three different schedules of preoperative&#xD;
      ipilimumab and nivolumab. Urothelial cancer patients will be included that are diagnosed with&#xD;
      either:&#xD;
&#xD;
        -  cT3-4aN0M0 OR&#xD;
&#xD;
        -  T1-4aN1-3M0&#xD;
&#xD;
      Cohort 1 (n=24) (Completed):&#xD;
&#xD;
        -  Day 1: Ipilimumab 3 mg/kg&#xD;
&#xD;
        -  Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg&#xD;
&#xD;
        -  Day 43: Nivolumab 3 mg/kg&#xD;
&#xD;
        -  Day 56-84: Radical cystectomy or nefro/ureterectomy with appropriate lymph node&#xD;
           dissection&#xD;
&#xD;
      Patients in cohort 2 (n=30) will be randomized between cohort 2a and 2b&#xD;
&#xD;
      Cohort 2a (n=15):&#xD;
&#xD;
        -  Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg&#xD;
&#xD;
        -  Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg&#xD;
&#xD;
        -  Day 43: Nivolumab 3 mg/kg&#xD;
&#xD;
        -  Day 56-84: Radical cystectomy or nefro/ureterectomy with appropriate lymph node&#xD;
           dissection&#xD;
&#xD;
      Cohort 2b (n=15):&#xD;
&#xD;
        -  Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg&#xD;
&#xD;
        -  Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg&#xD;
&#xD;
        -  Day 43: Nivolumab 3 mg/kg&#xD;
&#xD;
        -  Day 56-84: Radical cystectomy or nefro/ureterectomy with appropriate lymph node&#xD;
           dissection&#xD;
&#xD;
      The primary endpoint for cohort 1 in this trial is safety. We will determine the number of&#xD;
      patients that have surgical resection &lt;12 weeks from first infusion, as this is an endpoint&#xD;
      that is clinically meaningful for this population. After surgery, patients attend study&#xD;
      visits at day 8 and day 29 . Their final study visit for physical examination and laboratory&#xD;
      testing is at day 57 (+/- 7 days), which is scheduled to anticipate late-onset adverse events&#xD;
      (particularly endocrine). After this final visit, patients will be followed according to&#xD;
      standard clinical guidelines. Tumor biopsies/material preservation is required at baseline&#xD;
      and during surgery.&#xD;
&#xD;
      In cohort 2, we will randomize patients between 2 arms. Here, the main secondary outcomes&#xD;
      are:&#xD;
&#xD;
        -  To compare the efficacy of pre-operative ipilimumab + nivolumab in cohort 1 (sequenced&#xD;
           ipilimumab/nivolumab), versus cohort 2a (ipi 3 mg/kg and nivo 1 mg/kg) and cohort 2b&#xD;
           (ipi 1 mg/kg and nivo 3 mg/kg). Efficacy is defined as pCR rate at resection.&#xD;
&#xD;
        -  Provide an estimate of ≥grade 3 immune-related toxicity in the ipi3/nivo1 and ipi1/nivo3&#xD;
           cohorts as opposed to the initial cohort (Cohort 1)&#xD;
&#xD;
      An important additional secondary endpoint is translational. The main testable hypothesis is&#xD;
      that a significant percentage of nonresponse can be explained by immune-inhibitory processes.&#xD;
      Absence of immune infiltrates, presence of significant numbers of regulatory T-cells and&#xD;
      presence of significant numbers of myeloid-derived suppressor cells will be compared between&#xD;
      responders and nonresponders. The efficacy will be defined as the percentage of pathological&#xD;
      complete response (pCR) at cystectomy (secondary endpoint).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Actual">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, open-label phase 1b clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that have surgical resection &lt;12 weeks after study start (Cohort 1)</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Percentage of patients that underwent surgery within 12 weeks after study start will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of immunotherapy, assessed by by the percentage of pathological complete response rate (pCR) after cystectomy (Cohort 1, followed by Cohort 2a versus 2b)</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>pCR rate after cystectomy according to pathological response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in immune infiltrates in responders vs nonresponders</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Resistance mechanisms are explored by comparing immune (cell) infiltrates in responders and nonresponders in pre- and post treatment tissue [Multiplex immunohistochemistry, RNA seq]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell (dys)functionality as measured by comparing the transcriptome of tumor-specific T cells in intra-patient pre- and post therapy tissue</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>This component is done in a minority of patients on T cell lysates if a re-TUR (transurethral resection) pre-treatment was done.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore whether radiomics-based predictive models can be established for immunotherapy responders vs non-responders (Cohort 1)</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>CT and MRI images will be assessed in this manner to optimize recognition of an immunotherapy response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provide an estimate of ≥grade 3 immune-related toxicity in cohorts 2a versus 2b</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Immune-related toxicity will be compared versus cohort 1 and between cohorts 2a and 2b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitor peri-surgical complications.</measure>
    <time_frame>Until 90 days after surgery.</time_frame>
    <description>peri-operative complications and morbidity will be graded according to the Clavien-Dindo classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>As part of regular follow-up after radical surgery, follow-up CT scans will we be made after 1 and 2 years.</measure>
    <time_frame>Until 2 years after surgery.</time_frame>
    <description>As part of regular follow-up after radical surgery, follow-up CT scans will we be made after 1 and 2 years. Additional scans should be performed according to local standards.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Ipi + Nivo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Ipilimumab 3 mg/kg i.v.&#xD;
Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.&#xD;
Day 43: Nivolumab 3 mg/kg i.v.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a: high-Ipi + low-Nivo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.&#xD;
Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.&#xD;
Day 43: Nivolumab 3 mg/kg i.v.&#xD;
Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b: low-Ipi + high-Nivo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.&#xD;
Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.&#xD;
Day 43: Nivolumab 3 mg/kg i.v.&#xD;
Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>For Cohort 1:&#xD;
Day 1: Ipilimumab 3 mg/kg&#xD;
Days 22: Ipilimumab 3 mg/kg&#xD;
For Cohort 2a:&#xD;
Day 1: Ipilimumab 3 mg/kg&#xD;
Days 22: Ipilimumab 3 mg/kg&#xD;
For Cohort 2b:&#xD;
Day 1: Ipilimumab 1 mg/kg&#xD;
Days 22: Ipilimumab 1 mg/kg</description>
    <arm_group_label>Cohort 1: Ipi + Nivo</arm_group_label>
    <arm_group_label>Cohort 2a: high-Ipi + low-Nivo</arm_group_label>
    <arm_group_label>Cohort 2b: low-Ipi + high-Nivo</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>For Cohort 1:&#xD;
Day 22: Nivolumab 1 mg/kg&#xD;
Day 43: Nivolumab 3 mg/kg&#xD;
For Cohort 2a:&#xD;
Days 1 and 22: Nivolumab 1 mg/kg&#xD;
Day 43: Nivolumab 3 mg/kg&#xD;
For Cohort 2b:&#xD;
- Days 1, 22 and 43: Nivolumab 3 mg/kg</description>
    <arm_group_label>Cohort 1: Ipi + Nivo</arm_group_label>
    <arm_group_label>Cohort 2a: high-Ipi + low-Nivo</arm_group_label>
    <arm_group_label>Cohort 2b: low-Ipi + high-Nivo</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. High-risk resectable urothelial cancer (upper urinary tract allowed) defined as stage&#xD;
             III UC:&#xD;
&#xD;
        cT3-4aN0M0 OR cT1-4aN1-3M0 4. Refusal of neoadjuvant/induction cisplatin-based chemotherapy&#xD;
        or patients in whom neoadjuvant cisplatin based therapy is not appropriate.&#xD;
&#xD;
        5. World Health Organization (WHO) performance Status 0 or 1. 6. Urothelial cancer is the&#xD;
        dominant histology (&gt;70%). 7. Formalin-fixed paraffin-embedded (FFPE) tumor specimens in&#xD;
        paraffin blocks from diagnostic TUR available (or any other FFPE tumor specimens for upper&#xD;
        tract tumors).8. Screening laboratory values must meet the following criteria: WBC ≥&#xD;
        2.0x109/L, Neutrophils ≥1.0x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, GFR&gt;30&#xD;
        ml/min, AST ≤ 2.5 x ULN, ALT ≤2.5 x ULN, Bilirubin ≤1.5 X ULN 9. Negative pregnancy test&#xD;
        within 2 weeks of Day 1 Cycle 1 for female patients of childbearing potential.&#xD;
&#xD;
        10. For female patients of childbearing potential to use a highly effecting form(s) of&#xD;
        contraception (i.e. one that results in a low failure rate [&lt;1% per year] when used&#xD;
        consistently and correctly) and to continue its use for 180 days after the last dose of&#xD;
        immunotherapy Adequate contraceptive methods are: condom, sterilization, other barrier&#xD;
        contraceptive measures preferably in combination with condoms, oral contraceptives,&#xD;
        intra-uterine device.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with active autoimmune disease in the past 2 years. Patients with diabetes&#xD;
             mellitus, properly controlled hypothyroidism or hyperthyroidism, vitiligo, psoriasis&#xD;
             or other mild skin disease can still be included.&#xD;
&#xD;
          2. Documented history of severe autoimmune disease (e.g. inflammatory bowel disease,&#xD;
             myasthenia gravis).&#xD;
&#xD;
          3. Prior CTLA-4 or PD-1/PD-L1-targeting immunotherapy.&#xD;
&#xD;
          4. Known history of Human Immunodeficiency Virus, positive tests for Hepatitis B surface&#xD;
             antigen or Hepatitis C ribonucleic acid (RNA), active tuberculosis, or other active&#xD;
             infection requiring therapy at the time of inclusion.&#xD;
&#xD;
          5. Underlying medical conditions that, in the investigator's opinion, will make the&#xD;
             administration of study drug hazardous or obscure the interpretation of adverse events&#xD;
&#xD;
          6. Medical condition requiring the use of immunosuppressive medications, with the&#xD;
             exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at&#xD;
             physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent&#xD;
             corticosteroid. Steroids as premedication for hypersensitivity reactions (eg, CT scan&#xD;
             premedication) will be allowed.&#xD;
&#xD;
          7. Use of other investigational drugs before study drug administration&#xD;
&#xD;
          8. Malignancy, other than urothelial cancer, in the previous 2 years, with a high chance&#xD;
             of recurrence (estimated &gt;10%). Patients with low risk prostate cancer (defined as&#xD;
             Stage T1/T2a, Gleason score&#xD;
&#xD;
             ≤ 6, and PSA ≤ 10 ng/mL) who are treatment-naive and undergoing active surveillance&#xD;
             are eligible.&#xD;
&#xD;
          9. Pregnant and lactating female patients.&#xD;
&#xD;
         10. Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for&#xD;
             a major surgical procedure during the course of the study other than for diagnosis.&#xD;
&#xD;
         11. Severe infections within 4 weeks prior to enrolment in the study including but not&#xD;
             limited to hospitalization for complications of infection, bacteraemia, or severe&#xD;
             pneumonia.&#xD;
&#xD;
         12. Significant cardiovascular disease, such as New York Heart Association cardiac disease&#xD;
             (Class II or greater), myocardial infarction within 3 months prior to enrolment,&#xD;
             unstable arrhythmias, or unstable angina.&#xD;
&#xD;
         13. Previous intravenous chemotherapy for bladder cancer. Prior chemoradiation is allowed.&#xD;
&#xD;
         14. Patients in whom use of a colon segment for urinary diversion is planned&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michiel MS van der Heijden, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>December 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2018</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urothelial cancer</keyword>
  <keyword>Bladder cancer</keyword>
  <keyword>Cancer</keyword>
  <keyword>Resectable</keyword>
  <keyword>Operable</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Neo-Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

